{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:17:38Z","timestamp":1763662658904},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biosci"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s12038-007-0051-y","type":"journal-article","created":{"date-parts":[[2007,5,26]],"date-time":"2007-05-26T14:01:01Z","timestamp":1180188061000},"page":"517-530","source":"Crossref","is-referenced-by-count":292,"title":["Heat shock protein 90: The cancer chaperone"],"prefix":"10.1007","volume":"32","author":[{"given":"Len","family":"Neckers","sequence":"first","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2007,5,27]]},"reference":[{"key":"51_CR1","first-page":"2505","volume":"8","author":"C. Aghajanian","year":"2002","unstructured":"Aghajanian C, Soignet S, Dizon D S, Pien C S, Adams J, Elliott P J, Sabbatini P, Miller V, Hensley M L, Pezzulli S, Canales C, Daud A and Spriggs D R 2002 A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies; Clin. Cancer Res. 8 2505\u20132511","journal-title":"Clin. Cancer Res."},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1073\/pnas.0500055102","volume":"102","author":"N. Agrawal","year":"2005","unstructured":"Agrawal N, Pallos J, Slepko N, Apostol B L, Bodai L, Chang L-W, Chiang A-S, Thompson L M and Marsh J L 2005 Identification of combinatorial drug regimens for treatment of Huntington\u2019s disease using Drosophila; Proc. Natl. Acad. Sci. USA 102 3777\u20133781","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1128\/MCB.18.9.4949","volume":"18","author":"A. Ali","year":"1998","unstructured":"Ali A, Bharadwaj S, O\u2019Carroll R and Ovsenek N 1998 HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes; Mol. Cell. Biol. 18 4949\u20134960","journal-title":"Mol. Cell. Biol."},{"key":"51_CR4","first-page":"355","volume":"11","author":"W. G. An","year":"2000","unstructured":"An, W G, Schulte, T W and Neckers, L M 2000 The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome; Cell Growth Differ. 11 355\u2013360","journal-title":"Cell Growth Differ."},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nm1102-1185","volume":"8","author":"P. K. Auluck","year":"2002","unstructured":"Auluck P K and Bonini, N M. 2002b Pharmacological prevention of Parkinson disease in Drosophila; Nat. Med. 8 1185\u20131186","journal-title":"Nat. Med."},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.1067389","volume":"295","author":"P. K. Auluck","year":"2002","unstructured":"Auluck P K, Chan H Y, Trojanowski J Q, Lee V M-Y and Bonini N M 2002a Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson\u2019s disease; Science 295 865\u2013868","journal-title":"Science"},{"key":"51_CR7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4161\/cbt.3.10.1142","volume":"3","author":"R. Bagatell","year":"2004","unstructured":"Bagatell R and Whitesell L 2004 Altered Hsp90 function in cancer: a unique therapeutic opportunity; Mol. Cancer Ther. 3 1021\u20131030","journal-title":"Mol. Cancer Ther."},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-05-0344","volume":"11","author":"P. Bali","year":"2005","unstructured":"Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang H G, Richon V and Bhalla K 2005 Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2; Clin. Cancer Res. 11 6382\u20136389","journal-title":"Clin. Cancer Res."},{"key":"51_CR9","unstructured":"Banerji U, O\u2019Donnell A, Scurr M, Benson C, Hanwell J, Clark S, Raynaud F, Turner A, Walton M, Workman P and Judson I 2001 Phase I Trial of the Heat Shock Protein 90 (HSP90) Inhibitor 17-Allylamino 17-Demethoxygeldanamycin 17aag). Pharmacokinetic (PK) Profile and Pharmacodynamic (PD) Endpoints; Proc. Am. Soc. Clin. Oncol. 20 abstract 326"},{"key":"51_CR10","unstructured":"Banerji U, O\u2019Donnell A, Scurr M, Benson C, Stapleton S, Raynaud F, Clarke S, Turner A, Workman P and Judson I 2003 A pharmacokinetically (PK) \u2014 pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG); Proc. Am. Soc. Clin. Oncol. 22 abstract 797"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","volume":"23","author":"U. Banerji","year":"2005","unstructured":"Banerji U, O\u2019donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P and Judson I 2005 Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies; J. Clin. Oncol. 23 4152\u20134161","journal-title":"J. Clin. Oncol."},{"key":"51_CR12","unstructured":"Banerji U, O\u2019Donnell A, Scurr M, Benson C, Brock C, Hanwell J, Stapleton S, Raynaud F, Simmons L, Turner A, Walton M, Workman P and Judson I 2002 A pharmacokinetically (Pk) \u2014 pharmacodynamically (Pd) driven phase I trial of the Hsp90 molecular chaperone inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG); Proc. 93rd Annu. Meet Am. Assoc. Cancer Res. 43 Abstract 1352"},{"key":"51_CR13","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M206322200","volume":"277","author":"A. D. Basso","year":"2002","unstructured":"Basso A D, Solit D B, Chiosis G, Giri B, Tsichlis P and Rosen N 2002 Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function; J. Biol. Chem. 277 39858\u201339866","journal-title":"J. Biol. Chem."},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.0906-6705.2004.00114.x","volume":"13","author":"B. Becker","year":"2004","unstructured":"Becker B, Multhoff G, Farkas B, Wild P J, Landthaler M, Stolz W and Vogt T 2004 Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases; Exp. Dermatol. 13 27\u201332","journal-title":"Exp. Dermatol."},{"key":"51_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00689804","volume":"12","author":"M. Belinsky","year":"1993","unstructured":"Belinsky M and Jaiswal A K 1993 NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues; Cancer Metastasis Rev. 12 103\u2013117","journal-title":"Cancer Metastasis Rev."},{"key":"51_CR16","first-page":"8984","volume":"63","author":"K. S. Bisht","year":"2003","unstructured":"Bisht K S, Bradbury C M, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz K L, Sieck L K, Isaacs J S, Brechbiel M W, Mitchell J B, Neckers L M and Gius D 2003 Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signalling and cytotoxicity; Cancer Res. 63 8984\u20138995","journal-title":"Cancer Res."},{"key":"51_CR17","first-page":"1559","volume":"62","author":"P. Bonvini","year":"2002","unstructured":"Bonvini P, Gastaldi T, Falini B and Rosolen A 2002 Nucleophosminanaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin; Cancer Res. 62 1559\u20131566","journal-title":"Cancer Res."},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/423593a","volume":"423","author":"D. P. Bottaro","year":"2003","unstructured":"Bottaro D P and Liotta L A 2003 Out of air is not out of action; Nature (London) 423 593\u2013595","journal-title":"Nature (London)"},{"key":"51_CR19","unstructured":"Burger A M, Fiebig H H, Newman D J, Camalier R F and Sausville E A 1998 Antitumor activity of 17-allylaminogeldanamycin (NSC 330507) in melanoma xenografts is associated with decline in Hsp90 protein expression; 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, abstract 504"},{"key":"51_CR20","unstructured":"Burger A M, Sausville E A, Carmalier R F, Newman D J and Fiebig H H 2000 Response of human melanomas to 17-AAG is associated with modulation of the molecular chaperone function of Hsp90; Proc. Am. Assoc. Cancer Res. 41 abstract 2844"},{"key":"51_CR21","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1016\/j.bmcl.2005.05.046","volume":"15","author":"K. M. Cheung","year":"2005","unstructured":"Cheung K M, Matthews T P, James K Rowlands M G, Boxall K J, Sharp S Y, Maloney A, Roe S M, Prodromou C, Pearl L H, Aherne G W, McDonald E and Workman P 2005 The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors; Bioorg. Med. Chem. Lett. 15 3338\u20133343","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4161\/cbt.2.2.235","volume":"2","author":"G. Chiosis","year":"2003","unstructured":"Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L and Neckers L 2003 17AAG: Low Target Binding Affinity and Potent Cell Activity-Finding an Explanation; Mol. Cancer Ther. 2 123\u2013129","journal-title":"Mol. Cancer Ther."},{"key":"51_CR23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/1568009033481778","volume":"3","author":"G. Chiosis","year":"2003","unstructured":"Chiosis G, Lucas B, Huezo H, Solit D, Basso A and Rosen N 2003 Development of purine-scaffold small molecule inhibitors of Hsp90; Curr. Cancer Drug Targets 3 371\u2013376","journal-title":"Curr. Cancer Drug Targets"},{"key":"51_CR24","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/S0968-0896(02)00253-5","volume":"10","author":"G. Chiosis","year":"2002","unstructured":"Chiosis G, Lucas B, Shtil A, Huezo H and Rosen N 2002 Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase; Bioorg. Med. Chem. 10 3555\u20133564","journal-title":"Bioorg. Med. Chem."},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1359-6446(04)03245-3","volume":"9","author":"G. Chiosis","year":"2004","unstructured":"Chiosis G, Vilenchik M, Kim J and Solit D 2004 Hsp90: the vulnerable chaperone; Drug Discov. Today 9 881\u2013888","journal-title":"Drug Discov. Today"},{"key":"51_CR26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/jmbi.1999.2990","volume":"293","author":"F. E. Cohen","year":"1999","unstructured":"Cohen F E 1999 Protein misfolding and prion diseases; J. Mol. Biol. 293 313\u2013320","journal-title":"J. Mol. Biol."},{"key":"51_CR27","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1067\/msy.2002.128562","volume":"132","author":"M. S. Cohen","year":"2002","unstructured":"Cohen M S, Hussain H B and Moley J F 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors; Surgery 132 960\u2013966; discussion 966\u2013967","journal-title":"Surgery"},{"key":"51_CR28","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1158\/0008-5472.CAN-05-2632","volume":"65","author":"S. Rocha Dias da","year":"2005","unstructured":"da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P and Marais R 2005 Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin; Cancer Res. 65 10686\u201310691","journal-title":"Cancer Res."},{"key":"51_CR29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.7164\/antibiotics.23.442","volume":"23","author":"C. DeBoer","year":"1970","unstructured":"DeBoer C, Meulman P A, Wnuk R J and Peterson D H 1970 Geldanamycin, a new antibiotic; J. Antibiot. (Tokyo) 23 442\u2013447","journal-title":"J. Antibiot. (Tokyo)"},{"key":"51_CR30","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.V99.7.2532","volume":"99","author":"S. Dias","year":"2002","unstructured":"Dias S, Shmelkov S V, Lam G and Rafii S 2002 VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition; Blood 99 2532\u20132540","journal-title":"Blood"},{"key":"51_CR31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"B. J. Druker","year":"1996","unstructured":"Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J and Lydon N B 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells; Nat. Med. 2 561\u2013566","journal-title":"Nat. Med."},{"key":"51_CR32","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/jm050355z","volume":"48","author":"B. W. Dymock","year":"2005","unstructured":"Dymock B W, Barril X, Brough P A, Cansfield J E, Massey A, McDonald E, Hubbard R E, Surgenor A, Roughley S D, Webb P, Workman P, Wright L and Drysdale M J 2005 Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design; J. Med. Chem. 48 4212\u20134215","journal-title":"J. Med. Chem."},{"key":"51_CR33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-001-0380-8","volume":"49","author":"M. J. Egorin","year":"2002","unstructured":"Egorin M J, Lagattuta T F, Hamburger D R, Covey J M, White K D, Musser S M and Eiseman J L 2002 Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats; Cancer Chemother. Pharmacol. 49 7\u201319","journal-title":"Cancer Chemother. Pharmacol."},{"key":"51_CR34","first-page":"2385","volume":"58","author":"M. J. Egorin","year":"1998","unstructured":"Egorin M J, Rosen D M, Wolff J H, Callery P S, Musser S M and Eiseman J L 1998 Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations; Cancer Res. 58 2385\u20132396","journal-title":"Cancer Res."},{"key":"51_CR35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-004-0865-3","volume":"55","author":"J. L. Eiseman","year":"2005","unstructured":"Eiseman J L, Lan J, Lagattuta T F, Hamburger D R, Joseph E, Covey J M and Egorin M J 2005 Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts; Cancer Chemother. Pharmacol. 55 21\u201332","journal-title":"Cancer Chemother. Pharmacol."},{"key":"51_CR36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.4161\/cc.3.9.1088","volume":"3","author":"B. K. Eustace","year":"2004","unstructured":"Eustace B K and Jay D G 2004 Extracellular Roles for the Molecular Chaperone, hsp90; Cell Cycle 3 1098\u20131100","journal-title":"Cell Cycle"},{"key":"51_CR37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/ncb1131","volume":"6","author":"B. K. Eustace","year":"2004","unstructured":"Eustace B K, Sakurai T, Stewart J K, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning S W, Beste G, Scroggins B T, Neckers L, Ilag L L and Jay D G 2004 Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness; Nat. Cell Biol. 6 507\u2013514","journal-title":"Nat. Cell Biol."},{"key":"51_CR38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","volume":"404","author":"M. B. Feany","year":"2000","unstructured":"Feany M B and Bender W W 2000 A Drosophila model of Parkinson\u2019s disease; Nature (London) 404 394\u2013398","journal-title":"Nature (London)"},{"key":"51_CR39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/exmp.2001.2401","volume":"71","author":"B. A. French","year":"2001","unstructured":"French B A, van Leeuwen F, Riley N E, Yuan Q X, Bardag-Gorce F, Gaal K, Lue Y H, Marceau N and French S W 2001 Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin; Exp. Mol. Pathol. 71 241\u2013246","journal-title":"Exp. Mol. Pathol."},{"key":"51_CR40","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1073\/pnas.93.9.4181","volume":"93","author":"J. Fujimoto","year":"1996","unstructured":"Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S and Yamamoto T 1996 Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5); Proc. Natl. Acad. Sci. USA 93 4181\u20134186","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51_CR41","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","volume":"103","author":"G. Fumo","year":"2004","unstructured":"Fumo G, Akin C, Metcalfe D D and Neckers L 2004 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells; Blood 103 1078\u20131084","journal-title":"Blood"},{"key":"51_CR42","doi-asserted-by":"crossref","first-page":"11824","DOI":"10.1021\/bi0259150","volume":"41","author":"V. Georget","year":"2002","unstructured":"Georget V, Terouanne B, Nicolas, J-C and Sultan C 2002 Mechanism of antiandrogen action: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor; Biochemistry 41 11824\u201311831","journal-title":"Biochemistry"},{"key":"51_CR43","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1242\/jeb.01034","volume":"207","author":"R. G. Giffard","year":"2004","unstructured":"Giffard R G, Xu L, Zhao H, Carrico W, Ouyang Y B, Qiao Y, Sapolsky R, Steinberg G, Hu B and Yenari M A 2004 Chaperones, protein aggregation, and brain protection from hypoxic\/ischemic injury; J. Exp. Biol. 207 3213\u20133220","journal-title":"J. Exp. Biol."},{"key":"51_CR44","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/annonc\/mdg316","volume":"14","author":"M. P. Goetz","year":"2003","unstructured":"Goetz M P, Toft D O, Ames M M and Erlichman C 2003 The Hsp90 chaperone complex as a novel target for cancer therapy; Ann. Oncol. 14 1169\u20131176","journal-title":"Ann. Oncol."},{"key":"51_CR45","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","volume":"100","author":"M. E. Gorre","year":"2002","unstructured":"Gorre M E, Ellwood-Yen K, Chiosis G, Rosen N and Sawyers C L 2002 BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90; Blood 100 3041\u20133044","journal-title":"Blood"},{"key":"51_CR46","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1128\/MCB.16.10.5221","volume":"16","author":"K. Gradin","year":"1996","unstructured":"Gradin K, McGuire J, Wenger R H, Kvietikova I, fhitelaw M L, Toftgard R, Tora L, Gassmann M and Poellinger L 1996 Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor; Mol. Cell Biol. 16 5221\u20135231","journal-title":"Mol. Cell Biol."},{"key":"51_CR47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1073\/pnas.0609973103","volume":"103","author":"O. M. Grbovic","year":"2006","unstructured":"Grbovic O M, Basso A, Sawai A, Ye Q, Friedlander P, Solit D and Rosen N 2006 V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors; Proc. Natl. Acad. Sci. USA 103 57\u201362","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51_CR48","doi-asserted-by":"crossref","first-page":"10006","DOI":"10.1158\/0008-5472.CAN-05-2029","volume":"65","author":"W. Guo","year":"2005","unstructured":"Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D and Ross D 2005 Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition; Cancer Res. 65 10006\u201310015","journal-title":"Cancer Res."},{"key":"51_CR49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrc795","volume":"2","author":"W. C. Hahn","year":"2002","unstructured":"Hahn W C and Weinberg R A 2002 Modelling the molecular circuitry of cancer; Nat. Rev. Cancer 2 331\u2013341","journal-title":"Nat. Rev. Cancer"},{"key":"51_CR50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D. Hanahan","year":"2000","unstructured":"Hanahan D and Weinberg R A 2000 The hallmarks of cancer; Cell 100 57\u201370","journal-title":"Cell"},{"key":"51_CR51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"A. L. Harris","year":"2002","unstructured":"Harris A L 2002 Hypoxia-a key regulatory factor in tumor growth; Nat. Rev. Cancer 2 38\u201347","journal-title":"Nat. Rev. Cancer"},{"key":"51_CR52","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/hmg\/ddh144","volume":"13","author":"D. G. Hay","year":"2004","unstructured":"Hay D G, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith D L, Woodman B and Bates G P 2004 Progressive decrease in chaperone protein levels in a mouse model of Huntington\u2019s disease and induction of stress proteins as a therapeutic approach; Hum. Mol. Genet. 13 1389\u20131405","journal-title":"Hum. Mol. Genet."},{"key":"51_CR53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0508078","volume":"49","author":"H. He","year":"2006","unstructured":"He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino R M, Gewirth D T and Chiosis G 2006 Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90; J. Med. Chem. 49 381\u2013390","journal-title":"J. Med. Chem."},{"key":"51_CR54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A. Hershko","year":"1998","unstructured":"Hershko A and Ciechanover A 1998 The ubiquitin system; Annu. Rev. Biochem. 67 425\u2013479","journal-title":"Annu. Rev. Biochem."},{"key":"51_CR55","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1523\/JNEUROSCI.20-09-03191.2000","volume":"20","author":"B. R. Hu","year":"2000","unstructured":"Hu B R, Martone M E, Jones Y Z and Liu C L 2000 Protein aggregation after transient cerebral ischemia; J. Neurosci. 20 3191\u20133199","journal-title":"J. Neurosci."},{"key":"51_CR56","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1124\/mol.62.5.975","volume":"62","author":"E. Hur","year":"2002","unstructured":"Hur E, Kim H H, Choi S M, Kim J H, Yim S, Kwon H J, Choi Y, Kim, D K, Lee M O and Park H 2002 Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha\/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol; Mol. Pharmacol. 62 975\u2013982","journal-title":"Mol. Pharmacol."},{"key":"51_CR57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(03)00456-7","volume":"204","author":"M. Ichihara","year":"2004","unstructured":"Ichihara M, Murakumo Y and Takahashi M 2004 RET and neuroendocrine tumors; Cancer Lett. 204 197\u2013211","journal-title":"Cancer Lett."},{"key":"51_CR58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1517\/13543784.14.6.569","volume":"14","author":"J. S. Isaacs","year":"2005","unstructured":"Isaacs J S 2005 Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?; Expert. Opin. Investig. Drugs 14 569\u2013589","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"51_CR59","doi-asserted-by":"crossref","first-page":"29936","DOI":"10.1074\/jbc.M204733200","volume":"277","author":"J. S. Isaacs","year":"2002","unstructured":"Isaacs J S, Jung Y J, Mimnaugh E G, Martinez A, Cuttitta F and Neckers L M 2002 Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway; J. Biol. Chem. 277 29936\u201329944","journal-title":"J. Biol. Chem."},{"key":"51_CR60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1535-6108(03)00029-1","volume":"3","author":"J. S. Isaacs","year":"2003","unstructured":"Isaacs J S, Xu W and Neckers L 2003 Heat shock protein 90 as a molecular target for cancer therapeutics; Cancer Cell 3 213\u2013217","journal-title":"Cancer Cell"},{"key":"51_CR61","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/sj.onc.1203857","volume":"19","author":"S. M. Jhiang","year":"2000","unstructured":"Jhiang S M 2000 The RET proto-oncogene in human cancers; Oncogene 19 5590\u20135597","journal-title":"Oncogene"},{"key":"51_CR62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0168-9525(98)01559-5","volume":"14","author":"A. Kakizuka","year":"1998","unstructured":"Kakizuka A 1998 Protein precipitation: a common etiology in neurodegenerative disorders?; Trends Genet. 14 396\u2013402","journal-title":"Trends Genet."},{"key":"51_CR63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","volume":"425","author":"A. Kamal","year":"2003","unstructured":"Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M F, Fritz L C and Burrows F J 2003 A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors; Nature (London) 425 407\u2013410","journal-title":"Nature (London)"},{"key":"51_CR64","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jnci\/91.22.1940","volume":"91","author":"L. R. Kelland","year":"1999","unstructured":"Kelland L R, Sharp S Y, Rogers P M, Myers T G and Workman P 1999 DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90; J. Natl. Cancer Inst. 91 1940\u20131949","journal-title":"J. Natl. Cancer Inst."},{"key":"51_CR65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/713803536","volume":"48","author":"H. R. Kim","year":"1999","unstructured":"Kim H R, Kang H S and Kim H D 1999 Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells; IUBMB Life 48 429\u2013433","journal-title":"IUBMB Life"},{"key":"51_CR66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/426125a","volume":"426","author":"H. Kitano","year":"2003","unstructured":"Kitano H 2003 Cancer robustness: tumour tactics; Nature (London) 426 125","journal-title":"Nature (London)"},{"key":"51_CR67","doi-asserted-by":"crossref","first-page":"VI\/2","DOI":"10.1007\/s00415-004-1502-0","volume":"251","author":"R. Kruger","year":"2004","unstructured":"Kruger R 2004 Genes in familial parkinsonism and their role in sporadic Parkinson\u2019s disease; J. Neurol. (Suppl. 6) 251 VI\/2\u20136","journal-title":"J. Neurol. (Suppl. 6)"},{"key":"51_CR68","first-page":"29","volume":"89","author":"G. L\u2019Allemain","year":"2002","unstructured":"L\u2019Allemain G 2002 [Update on \u2026 the proteasome inhibitor PS341]; Bull. Cancer 89 29\u201330","journal-title":"Bull. Cancer"},{"key":"51_CR69","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","volume":"16","author":"P. Rosee La","year":"2002","unstructured":"La Rosee P, O\u2019Dwyer M E and Druker B J 2002 Insights from preclinical studies for new combination treatment regimens with the Bcr-Ab1 kinase inhibitor imatinib mesylate (Gleevec\/Glivec) in chronic myelogenous leukemia: a translational perspective; Leukemia 16 1213\u20131219","journal-title":"Leukemia"},{"key":"51_CR70","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1021\/jm049012b","volume":"48","author":"L. Llauger","year":"2005","unstructured":"Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies, P and Chiosis G 2005 Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90; J. Med. Chem. 48 2892\u20132905","journal-title":"J. Med. Chem."},{"key":"51_CR71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1471-4159.2002.00835.x","volume":"81","author":"A. Lu","year":"2002","unstructured":"Lu A, Ran R, Parmentier-Batteur S, Nee A and Sharp F R 2002 Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia; J. Neurochem. 81 355\u2013364","journal-title":"J. Neurochem."},{"key":"51_CR72","first-page":"2478","volume":"62","author":"N. J. Mabjeesh","year":"2002","unstructured":"Mabjeesh N J, Post D E, Willard M T, Kaur B, Van Meir E G, Simons J W and Zhong H 2002 Geldanamycin induces degradation of hypoxia-inducible factor 1\u03b1 protein via the proteasome pathway in prostate cancer cells; Cancer Res. 62 2478\u20132482","journal-title":"Cancer Res."},{"key":"51_CR73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/09553000310001626135","volume":"79","author":"H. Machida","year":"2003","unstructured":"Machida H, Matsumoto Y, Shirai M and Kubota N 2003 Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation; Int. J. Radiat. Biol. 79 973\u2013980","journal-title":"Int. J. Radiat. Biol."},{"key":"51_CR74","first-page":"620","volume":"8","author":"G. Maulik","year":"2002","unstructured":"Maulik G, Kijima T, Ma P C, Ghosh S K, Lin J, Shapiro G I, Schaefer E, Tibaldi E, Johnson B E and Salgia R 2002 Modulation of the c-Met\/hepatocyte growth factor pathway in small cell lung cancer; Clin. Cancer Res. 8 620\u2013627","journal-title":"Clin. Cancer Res."},{"key":"51_CR75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"P. H. Maxwell","year":"1999","unstructured":"Maxwell P H, Wiesener M S, Chang G-W, Clifford S C, Vaux E C, Cockman M E, Wykoff C C, Pugh C W, Maher E R and Ratcliffe P J 1999 The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis; Nature (London) 399 271\u2013275","journal-title":"Nature (London)"},{"key":"51_CR76","doi-asserted-by":"crossref","first-page":"22796","DOI":"10.1074\/jbc.271.37.22796","volume":"271","author":"E. G. Mimnaugh","year":"1996","unstructured":"Mimnaugh E G, Chavany C and Neckers L 1996 Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin; J. Biol. Chem. 271 22796\u201322801","journal-title":"J. Biol. Chem."},{"key":"51_CR77","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4161\/cbt.3.6.846","volume":"3","author":"E. G. Mimnaugh","year":"2004","unstructured":"Mimnaugh E G, Xu W, Vos M, Yuan X, Isaacs J S, Bisht K S, Gius D and Neckers L 2004 Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity; Mol. Cancer Ther. 3 551\u2013566","journal-title":"Mol. Cancer Ther."},{"key":"51_CR78","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/sj.leu.2402558","volume":"16","author":"Y. Minami","year":"2002","unstructured":"Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H and Naoe T 2002 Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors; Leukemia 16 1535\u20131540","journal-title":"Leukemia"},{"key":"51_CR79","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","volume":"99","author":"N. Mitsiades","year":"2002","unstructured":"Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann T A, Treon S P, Munshi N C, Richardson P G, Hideshima T and Anderson K C 2002 Molecular sequelae of proteasome inhibition in human multiple myeloma cells; Proc. Natl. Acad. Sci. USA 99 14374\u201314379","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51_CR80","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1007\/s002800100301","volume":"48","author":"T. Naoe","year":"2001","unstructured":"Naoe T, Kiyoe H, Yamamoto Y, Minami Y, Yamamoto K, Ueda R and Saito H 2001 FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy; Cancer Chemother. Pharmacol. 48 S27\u2013S30","journal-title":"Cancer Chemother. Pharmacol."},{"key":"51_CR81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.it.2005.11.009","volume":"27","author":"G. Nardai","year":"2006","unstructured":"Nardai G, Vegh E M, Prohaszka Z and Csermely P 2006 Chaperonerelated immune dysfunction: an emergent property of distorted chaperone networks; Trends Immunol. 27 74\u201379","journal-title":"Trends Immunol."},{"key":"51_CR82","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1471-4914(02)02316-X","volume":"8","author":"L. Neckers","year":"2002","unstructured":"Neckers L 2002 Hsp90 inhibitors as novel cancer chemotherapeutic agents; Trends Mol. Med. 8 S55\u2013S61","journal-title":"Trends Mol. Med."},{"key":"51_CR83","first-page":"5761","volume":"62","author":"R. Nimmanapalli","year":"2002","unstructured":"Nimmanapalli R, O\u2019Bryan E, Huang M, Bali P, Burnette P K, Loughran T, Tepperberg J, Jove R and Bhalla K 2002 Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin; Cancer Res. 62 5761\u20135769","journal-title":"Cancer Res."},{"key":"51_CR84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3940(00)01721-3","volume":"298","author":"Y. B. Ouyang","year":"2001","unstructured":"Ouyang Y B and Hu B R 2001 Protein ubiquitination in rat brain following hypoglycemic coma; Neurosci. Lett. 298 159\u2013162","journal-title":"Neurosci. Lett."},{"key":"51_CR85","unstructured":"Page J, Heath J, Fulton R et al 1997 Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin(NSC-330507D) toxicity in rats; Proc. Am. Assoc. Cancer Res. 38 abstract 2067"},{"key":"51_CR86","unstructured":"Paine-Murrieta G, Cook P, Taylor C W and Whitesell L 1999 The anti-tumor activity of 17-allylaminogeldanamycin is associated with modulation of target protein levels in vivo; Proc. Am. Assoc. Cancer Res. 40 abstract 119"},{"key":"51_CR87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","volume":"3","author":"S. Pennacchietti","year":"2003","unstructured":"Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S and Comoglio P M 2003 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene; Cancer Cell 3 347\u2013361","journal-title":"Cancer Cell"},{"key":"51_CR88","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccr.2005.03.035","volume":"7","author":"J. Plescia","year":"2005","unstructured":"Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone M G, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich D I, Colombo G and Altieri D C 2005 Rational design of shepherdin, a novel anticancer agent; Cancer Cell 7 457\u2013468","journal-title":"Cancer Cell"},{"key":"51_CR89","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"M. H. Polymeropoulos","year":"1997","unstructured":"Polymeropoulos M H, Lavedan C, Leroy E, Ide S E, Dehejia A, Dutra A, Pike B and Root H 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease; Science 276 2045\u20132047","journal-title":"Science"},{"key":"51_CR90","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1568009033481877","volume":"3","author":"C. Prodromou","year":"2003","unstructured":"Prodromou C and Pearl L H 2003 Structure and functional relationships of Hsp90; Curr. Cancer Drug Targets 3 301\u2013323","journal-title":"Curr. Cancer Drug Targets"},{"key":"51_CR91","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nature749","volume":"417","author":"C. Queitsch","year":"2002","unstructured":"Queitsch C, Sangster T A and Lindquist S 2002 Hsp90 as a capacitor of phenotypic variation; Nature (London) 417 618\u2013624","journal-title":"Nature (London)"},{"key":"51_CR92","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/418934a","volume":"418","author":"H. Rajagopalan","year":"2002","unstructured":"Rajagopalan H, Bardelli A, Lengauer C, Kinzler K W, Vogelstein B and Velculescu V E 2002 Tumorigenesis: RAF\/RAS oncogenes and mismatch-repair status; Nature (London) 418 934","journal-title":"Nature (London)"},{"key":"51_CR93","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/24550","volume":"396","author":"S. L. Rutherford","year":"1998","unstructured":"Rutherford S L and Lindquist S 1998 Hsp90 as a capacitor for morphological evolution; Nature (London) 396 336\u2013342","journal-title":"Nature (London)"},{"key":"51_CR94","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1749-6632.2002.tb04102.x","volume":"963","author":"M. Santoro","year":"2002","unstructured":"Santoro M, Melillo R M, Carlomagno F, Fusco A and Vecchio G 2002 Molecular mechanisms of RET activation in human cancer; Ann. N. Y. Acad. Sci. 963 116\u2013121","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"51_CR95","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"C. L. Sawyers","year":"2002","unstructured":"Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, Schiffer C A, Talpaz M et al 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study; Blood 99 3530\u20133539","journal-title":"Blood"},{"key":"51_CR96","doi-asserted-by":"crossref","first-page":"14536","DOI":"10.1073\/pnas.93.25.14536","volume":"93","author":"C. Schneider","year":"1996","unstructured":"Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N and Hartl F U 1996 Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90; Proc. Natl. Acad. Sci. USA 93 14536\u201314541","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51_CR97","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1021\/jm00019a011","volume":"38","author":"R. C. Schnur","year":"1995","unstructured":"Schnur R C, Corman M L, Gallaschun R J, Cooper B A, Dee M F, Doty J L, Muzzi M L, DiOrio C I, Barbacci E G, Miller P E et al 1995 erbB-2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships; J. Med. Chem. 38 3813\u20133820","journal-title":"J. Med. Chem."},{"key":"51_CR98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","volume":"42","author":"T. W. Schulte","year":"1998","unstructured":"Schulte T W and Neckers L M 1998 The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin; Cancer Chemother. Pharmacol. 42 273\u2013279","journal-title":"Cancer Chemother. Pharmacol."},{"key":"51_CR99","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","volume":"332","author":"B. R. Seizinger","year":"1988","unstructured":"Seizinger B R, Rouleau G A, Ozelius L J, Lane A H, Farmer G E, Lamiell J M, Haines J, Yuen J W, Collins D, Majoor-Krakauer D et al 1988 Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma; Nature (London) 332 268\u2013269","journal-title":"Nature (London)"},{"key":"51_CR100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"N. P. Shah","year":"2002","unstructured":"Shah N P, Nicoll J M, Nagar B, Gorre M E, Paquette R L, Kuriyan J and Sawyers C L 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia; Cancer Cell 2 117\u2013125","journal-title":"Cancer Cell"},{"key":"51_CR101","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1158\/0008-5472.CAN-05-0933","volume":"65","author":"T. Shimamura","year":"2005","unstructured":"Shimamura T, Lowell A M, Engelman J A and Shapiro G I 2005 Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins; Cancer Res. 65 6401\u20136408","journal-title":"Cancer Res."},{"key":"51_CR102","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood.V96.6.2284","volume":"96","author":"Y. Shiotsu","year":"2000","unstructured":"Shiotsu Y, Neckers L M, Wortman I, An W G, Schulte T W, Soga S, Murakata C, Tamaoki T and Akinaga S 2000 Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex; Blood 96 2284\u20132291","journal-title":"Blood"},{"key":"51_CR103","doi-asserted-by":"crossref","first-page":"51989","DOI":"10.1074\/jbc.M410562200","volume":"279","author":"G. Siligardi","year":"2004","unstructured":"Siligardi G, Hu B, Panaretou B, Piper P W, Pearl L H and Prodromou C 2004 Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle; J. Biol. Chem. 279 51989\u201351998","journal-title":"J. Biol. Chem."},{"key":"51_CR104","unstructured":"Solit D, Zheng F, Drobnjak M, Munster P, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus D, Scher H and Rosen N 2002 17-allylamino-17-demthoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts; Clin. Cancer Res. 986\u2013993"},{"key":"51_CR105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbapap.2003.11.027","volume":"1697","author":"A. S. Sreedhar","year":"2004","unstructured":"Sreedhar A S, Soti C and Csermely P 2004 Inhibition of Hsp90: a new strategy for inhibiting protein kinases; Biochim. Biophys. Acta 1697 233\u2013242","journal-title":"Biochim. Biophys. Acta"},{"key":"51_CR106","doi-asserted-by":"crossref","first-page":"15121","DOI":"10.1073\/pnas.96.26.15121","volume":"96","author":"D. L. Stoler","year":"1999","unstructured":"Stoler D L, Chen N, Basik M, Kahlenberg M S, Rodriguez-Bigas M A, Petrelli N J and Anderson G R 1999 The onset and extent of genomic instability in sporadic colorectal tumor progression; Proc. Natl. Acad. Sci. USA 96 15121\u201315126","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51_CR107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00689048","volume":"36","author":"J. G. Supko","year":"1995","unstructured":"Supko J G, Hickman R L, Grever M R and Malspeis L 1995 Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent; Cancer Chemother. Pharmacol. 36 305\u2013315","journal-title":"Cancer Chemother. Pharmacol."},{"key":"51_CR108","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/carcin\/22.9.1363","volume":"22","author":"L. Tacchini","year":"2001","unstructured":"Tacchini L, Dansi P, Matteucci E and Desiderio M A 2001 Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells; Carcinogenesis 22 1363\u20131371","journal-title":"Carcinogenesis"},{"key":"51_CR109","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1126\/science.1067122","volume":"296","author":"J. P. Taylor","year":"2002","unstructured":"Taylor J P, Hardy J and Fischbeck K H 2002 Toxic proteins in neurodegenerative disease; Science 296 1991\u20131995","journal-title":"Science"},{"key":"51_CR110","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/mds.20538","volume":"20","author":"G. K. Tofaris","year":"2005","unstructured":"Tofaris G K and Spillantini M G 2005 Alpha-synuclein dysfunction in Lewy body diseases; Mov. Disord. (Suppl 12) 20 S37\u2013S44","journal-title":"Mov. Disord. (Suppl 12)"},{"key":"51_CR111","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1379\/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2","volume":"7","author":"D. K. Vanaja","year":"2002","unstructured":"Vanaja D K, Mitchell S H, Toft D O and Young C Y F 2002 Effect of geldanamycin on androgen receptor function and stability; Cell Stress Chaperones 7 55\u201364","journal-title":"Cell Stress Chaperones"},{"key":"51_CR112","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2004.04.008","volume":"11","author":"M. Vilenchik","year":"2004","unstructured":"Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P and Chiosis G 2004 Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90; Chem. Biol. 11 787\u2013797","journal-title":"Chem. Biol."},{"key":"51_CR113","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1091\/mbc.12.5.1393","volume":"12","author":"S. Waelter","year":"2001","unstructured":"Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H and Wanker E E 2001 Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation; Mol. Biol. Cell 12 1393\u20131407","journal-title":"Mol. Biol. Cell"},{"key":"51_CR114","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm1298","volume":"11","author":"M. Waza","year":"2005","unstructured":"Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M and Sobue G 2005 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration; Nat. Med. 11 1088\u20131095","journal-title":"Nat. Med."},{"key":"51_CR115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10254-003-0021-1","volume":"151","author":"H. Wegele","year":"2004","unstructured":"Wegele H, Muller L and Buchner J 2004 Hsp70 and Hsp90-a relay team for protein folding; Rev. Physiol. Biochem. Pharmacol. 151 1\u201344","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"51_CR116","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2003.08.032","volume":"206","author":"P. Workman","year":"2004","unstructured":"Workman P 2004 Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone; Cancer Lett. 206 149\u2013157","journal-title":"Cancer Lett."},{"key":"51_CR117","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1025542026488","volume":"30","author":"L. Xu","year":"2003","unstructured":"Xu L, Eiseman, J L, Egorin, M J and D\u2019Argenio, D Z 2003 Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice; J. Pharmacokinet. Pharmacodyn. 30 185\u2013219","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"51_CR118","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/jnci\/94.7.504","volume":"94","author":"X. Yu","year":"2002","unstructured":"Yu X, Guo Z S, Marcu M G, Neckers L, Nguyen D M, Chen G A and Schrump D S 2002 Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228; J. Natl. Cancer Inst. 94 504\u2013513","journal-title":"J. Natl. Cancer Inst."},{"key":"51_CR119","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcp.10306","volume":"196","author":"D. Zagzag","year":"2003","unstructured":"Zagzag D, Nomura M, Friedlander D R, Blanco C, Gagner J P, Nomura N and Newcomb E W 2003 Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion; J. Cell Physiol. 196 394\u2013402","journal-title":"J. Cell Physiol."},{"key":"51_CR120","first-page":"488","volume":"82","author":"H. Zhang","year":"2004","unstructured":"Zhang H and Burrows F 2004 Targeting multiple signal transduction pathways through inhibition of Hsp90; J. Mol. Med. 82 488\u2013499","journal-title":"J. Mol. Med."},{"key":"51_CR121","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cell.2004.12.024","volume":"120","author":"R. Zhao","year":"2005","unstructured":"Zhao R, Davey M, Hsu Y C, Kaplanek P, Tong A, Parsons A B, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A and Houry W A 2005 Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone; Cell 120 715\u2013727","journal-title":"Cell"},{"key":"51_CR122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.neuro.23.1.217","volume":"23","author":"H. Y. Zoghbi","year":"2000","unstructured":"Zoghbi H Y and Orr H T 2000 Glutamine repeats and neurodegeneration; Annu. Rev. Neurosci. 23 217\u2013247","journal-title":"Annu. Rev. Neurosci."}],"container-title":["Journal of Biosciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12038-007-0051-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12038-007-0051-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12038-007-0051-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:46:25Z","timestamp":1587555985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12038-007-0051-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s12038-007-0051-y","relation":{},"ISSN":["0250-5991","0973-7138"],"issn-type":[{"value":"0250-5991","type":"print"},{"value":"0973-7138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}